invIOs to present progress across oncology pipeline during JP Morgan Week 2025 VIENNA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in...

invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology Funding secures ongoing pipeline progress and achievement of preclinical and clinical milestones Oral small molecule INV501: collaboration with Dana-Farber Cancer Institute (DFCI) making good...

Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting LONDON, April 10, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...

Achilles Therapeutics Announces Pricing of Initial Public Offering LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...